Neuroinflammation in Patients With OCD

Paused · Phase 2

Conditions studied: Obsessive-Compulsive Disorder

In brief

The goal of this study is to examine whether measurements of inflammation from brain scanning and blood tests can predict how much benefit patients with obsessive-compulsive disorder (OCD) will have from treatment with an anti-inflammatory medication, celecoxib, when adding to ongoing medication-based treatment for OCD.

Key facts

Study ID

NCT04786548

Run by

New York State Psychiatric Institute

People needed

21

Starts

2021-04-01

Expected to finish

2026-08-01

Last updated by the study team

2025-11-04

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 to 55 years old
• Principal diagnosis of Obsessive-Compulsive Disorder (OCD)
• Ongoing OCD symptoms despite current treatment with psychiatric medication
• Capacity to provide informed consent

You may not qualify if…

• Psychiatric comorbidities that would increase risk of participation or impact research measures (e.g., suicidality)
• Medical or neurological conditions that would increase risk of participation or impact research measures
• Contraindications to an MRI or PET scan (e.g., metal implants)
• Current use of medications that may interact with study drug or impact research measures (e.g., antipsychotics, corticosteroids, immunosuppressant medications, or daily non-steroidal anti-inflammatory medications)
• Starting a new evidence-based therapy for OCD (e.g., exposure with response prevention) 4 weeks prior to study enrollment

Where it is running

• New York State Psychiatric Institute — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.